Skip to content
ppharmaranks
Menu

Programmed Death Receptor-1 Blocking Antibody drugs compared

Compare all 2 Programmed Death Receptor-1 Blocking Antibody drugs side by side, used for conditions such as urinary bladder neoplasms, carcinoma, non-small-cell lung, carcinoma, squamous cell. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is opdivo.

Top-rated programmed death receptor-1 blocking antibody: 1. Opdivo · 2. Keytruda

Programmed Death Receptor-1 Blocking Antibody drugs compared side by side, with pharmaranks' FDA recall-safety rating
DrugGenericSafety ratingFDA recall-based
OpdivoNivolumab72/100
KeytrudaPembrolizumab70/100

The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.

Best programmed death receptor-1 blocking antibody by condition

Full ranking · 2 drugs

  1. 1

    opdivo

    Nivolumab

    72/100
  2. 2

    keytruda

    Pembrolizumab

    70/100

Frequently asked questions

What is the Programmed Death Receptor-1 Blocking Antibody drug class?

Programmed Death Receptor-1 Blocking Antibody is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 2 Programmed Death Receptor-1 Blocking Antibody products, each independently rated.

Are all Programmed Death Receptor-1 Blocking Antibody drugs the same?

No. Programmed Death Receptor-1 Blocking Antibody drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Programmed Death Receptor-1 Blocking Antibody drugs treat?

Per NIH RxClass drug-classification data, Programmed Death Receptor-1 Blocking Antibody drugs are used for conditions including urinary bladder neoplasms, carcinoma, non-small-cell lung, carcinoma, squamous cell, kidney neoplasms, lymphoma, melanoma.

Which Programmed Death Receptor-1 Blocking Antibody drug is best-rated?

By our independent rating, opdivo currently ranks highest among Programmed Death Receptor-1 Blocking Antibody drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.

Sources: the Programmed Death Receptor-1 Blocking Antibody class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.